GW Pharma to test cannabis as obesity therapy

GW Pharmaceuticals is planning to start human trials of a new obesity treatment derived from cannabis. A variety of drug developers, including Sanofi-Aventis, are working to develop therapies that snap the body's craving for food when they smoke cannabis. And researchers at the U.K. company say that cannabis itself contains clues to controlling obesity. Various ingredients in cannabis, they say, can both stimulate and suppress hunger.

- here's the report from MedIndia

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.